Not at all NYJG, remaining a sceptic of shorts is healthy...because they won't ever stop until they're satisfied. I just think management is much more equipped to deal with their BS so to speak.
I believe it was a little heavy, but relatively flat Q over Q. You're correct in that the mild winter up until December would hopefully add a few more MS exacerbations, but the future of Acthar with only 3% market penetration is phenomenal. Billions of dollars in income if the price is sustainable. May see a decrease in Acthar's selling price once some other generics come into play late 2010's or early 2020's. By then we may be in the 300's barring a correction :P
Until May of 2015. Supreme court might knock it down before then, and the $30,000/day in interest payments for everyday that they delay will light a fire under SIGA's #$%$ to settle and pay out.
I completely agree with you.
As for options, I like them as they help me make alot more money and hedge against volatility, but I think the weekly options contracts are ridiculous and open the stock up to ridiculous amounts of manipulation.
What do you mean by that Saram? Excluding one-time payments (I'm assuming put toward their debt) they're earning around $1.50/share per quarter.
And yes PJ is right, I meant Q's 1st quarter...running on old time.
You all need to face the music. Stop beating a dead horse and just come to terms with the fact that you've lost. After 8 years and 100's of millions it's just stupid not to take the proposed settlement with dignity and pay it off.
Unfortunately, we all know SIGA's management has no dignity whatsoever and will take the ship down before admitting defeat and getting back to business. Stupidity at its finest.
No you're absolutely right, my timing was off! Luckily it was a little more mild in the winter up until late December...now I'm freezing my buns off
They have a $5bln dollar buyback plan that I'd be surprised at if they didn't increase to $10bln. They're making money hand over fist and acquiring companies. The thing you need to understand is that much like another investment I used to own (QCOR), big players were manipulating the share price in order to keep it suppressed and flush out retail. Then, after there was just too much supporting evidence and the merger with mallinckrodt, the stock ran up immensely. Today, my QCOR is worth about $125/share from when I bought it at $23 in 2013. GILD has a much stronger pipeline and product line than Mallinckrodt, but the scenario is very similar. Someone (or many entities) are manipulating the stock at the expense of retail on unfounded opinions that create a cloud over the stock. With time, earnings, script data as evidence, and a strong pipeline GILD will have no choice but to move upwards.
People complain about many things with GILD, but one from a CNBC analyst (really commentator because they're just paid shills) said that the market cap is so large that a large move upward makes it overvalued on a cap basis.
For starters, lets focus strictly on market cap. GILD has revenues of $20 billion...at 10x sales that's a market cap of $200 billion. That's factoring in current quarterly revenue numbers (excluding this quarter), but leaves out the growth potential for HCV, HIV and all the other drugs in the pipeline.
Compare that to Celgene, who has lower revenue growth potential compared to existing products + pipeline than GILD and is also trading at roughly 11.8x revenue.
Not only that, but the market for HCV is upwards of $500bln globally and that's with a large discount in Hep C pricing over a 5 year period. Even 20% of that going to GILD over 5 years is $20bln a year strictly from Hep C.
This is the most undervalued company in the biotech sector.
I hope so too. I meant stabilize around $115 by end of Feb. The 1st quarter is usually lighter than the others for Acthar (huge sales driver), but the $900m in cash means a large increase in income and free cash flow. I hope I'm wrong and we skyrocket before then!
I wrote a lovely reply to you but Yahoo deleted it...in any case, thank you for the kind words. I just wanted to post that to note the price action after hours. If things stay on course fundamentally, without the market taking a bath or us releasing data updates/results, I wouldn't be surprised to see this hit $115 by end of February.
All small lots and all at $100/share. Scooped up very quickly I'm sure. Maybe Einhorn's finally realizing he's lost too much money on MNK?
Ah yeah, ah yeah, ah, ah, ah. Ah yeah, ah yeah, ah, ah, ah.
I gotta roll, can't stand still, got a flaming heart, can't get my fill
Eyes that shine burning red, dreams of you all through my head.
Ah ah ah ah ah ah ah ah ah ah ah ah ah.
Nevermind...watching his re-run he's saying it's undervalued...still dislike him though...he's a character for show that's about it.
Saw that as well...the fact that he slipped in the word "expensive" may trigger a little bit of selling tomorrow...he's such an idiot, couldn't pick a good stock if they offered to give him 50% equity and an inside look at their operations.
Humira coming off patent soon...generics enter and you see the market share of the drug deplete...I'd be surprised if they make 75% of branded Humira sales annually when it comes off patent protection.
It was a smart game all day...slowly let the shorts take it down and then run it up into the close so it breaks its resistance at $100/share and closes above there...should be a good few days